英國當局調查輝達收購Arm有否違反競爭法
英國競爭與市場管理局(CMA)已經對輝達(Nvidia)(NVDA.US)以400億美元收購英國晶片設計商Arm展開調查,之前Arm行政總裁Simon Segars在去年9月與輝達達成交易時已承認,要獲得全球監管機構的批准可能需時18個月。
Arm設計用於智能手機、電腦及平板電腦的晶片方面上處於全球領先地位,CMA表示,晶片技術行業價值屬數以十億美元計,對於日常生活中有重要作用,該局將與全球其他競爭監管機構緊密合作,仔細考慮交易所有的潛在影響,並確保最終不會導致消費者承受價格更高或質量下降的產品。
CMA續指,將研究交易對英國競爭環境的潛在影響,如果調查發現交易違反英國競爭規則,CMA可阻止今次收購。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.